Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules

Background and Aim:  Histamine 2 receptor antagonists and proton‐pump inhibitors, drugs that are widely used for the treatment of acid‐related diseases, have different clinical characteristics. The objective of this study was to compare the acid‐suppressing effects of ranitidine hydrochloride and th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2009-04, Vol.24 (4), p.639-645
Main Authors: Ono, Shouko, Kato, Mototsugu, Ono, Yuji, Imai, Aki, Yoshida, Takeshi, Shimizu, Yuichi, Asaka, Masahiro
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage
Adult
Anti-Ulcer Agents - administration & dosage
Biological and medical sciences
Cross-Over Studies
Digestive system
Drug Administration Schedule
Gastric Acid - secretion
Gastric Acidity Determination - instrumentation
Gastric Mucosa - drug effects
Gastric Mucosa - secretion
Gastroenterology. Liver. Pancreas. Abdomen
Helicobacter
histamine 2 receptor antagonist
Histamine H2 Antagonists - administration & dosage
Humans
Male
Medical sciences
Monitoring, Ambulatory - instrumentation
Pharmacology. Drug treatments
physiological monitoring
proton pump inhibitor
Proton Pump Inhibitors - administration & dosage
Rabeprazole
Ranitidine - administration & dosage
Telemetry - instrumentation
Time Factors
tolerance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim:  Histamine 2 receptor antagonists and proton‐pump inhibitors, drugs that are widely used for the treatment of acid‐related diseases, have different clinical characteristics. The objective of this study was to compare the acid‐suppressing effects of ranitidine hydrochloride and those of rabeprazole sodium at the first administration and re‐administration after withdrawal. Methods:  The study was designed as an open‐label, randomized, two‐way cross‐over trial. Seven Helicobacter pylori‐negative healthy volunteers were enrolled in this study. Ranitidine hydrochloride (300 mg/day) or rabeprazole sodium (20 mg/day) was administered from days 1 to 7 and from days 11 to 13. The percentage of time with gastric pH 
ISSN:0815-9319
1440-1746
DOI:10.1111/j.1440-1746.2008.05644.x